

Alicia C MarÃ-Ã-n

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7663822/publications.pdf>

Version: 2024-02-01

34
papers

2,327
citations

331538

21
h-index

377752

34
g-index

34
all docs

34
docs citations

34
times ranked

3411
citing authors

#	ARTICLE	IF	CITATIONS
1	Colonoscopy versus Fecal Immunochemical Testing in Colorectal-Cancer Screening. <i>New England Journal of Medicine</i> , 2012, 366, 697-706.	13.9	763
2	Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 613-623.	1.9	266
3	The Risk of Relapse after Anti-TNF Discontinuation in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2016, 111, 632-647.	0.2	156
4	Modifiable endoscopic factors that influence the adenoma detection rate in colorectal cancer screening colonoscopies. <i>Gastrointestinal Endoscopy</i> , 2013, 77, 381-389.e1.	0.5	125
5	Randomised clinical trial comparing sequential and concomitant therapies for <i>Helicobacter pylori</i> eradication in routine clinical practice. <i>Gut</i> , 2014, 63, 244-249.	6.1	119
6	Human intestinal pro-inflammatory CD11c ^{high} CCR2 ⁺ CX3CR1 ⁺ macrophages, but not their tolerogenic CD11c ⁺ CCR2 ⁺ CX3CR1 ⁺ counterparts, are expanded in inflammatory bowel disease. <i>Mucosal Immunology</i> , 2018, 11, 1114-1126.	2.7	105
7	Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti-TNF therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 391-405.	1.9	99
8	<i>Helicobacter pylori</i> second-line rescue therapy with levofloxacin and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 768-775.	1.9	91
9	A review of rescue regimens after clarithromycin-containing triple therapy failure (for <i>Helicobacter</i>) <i>Tj ETQq1 1 0.784314 rgBT /Overlo</i>	0.9	73
10	Third-Line Rescue Therapy with Bismuth-Containing Quadruple Regimen After Failure of Two Treatments (with Clarithromycin and Levofloxacin) for <i>H. pylori</i> Infection. <i>Digestive Diseases and Sciences</i> , 2014, 59, 383-389.	1.1	48
11	Correlation between adenoma detection rate in colonoscopy and fecal immunochemical testing-based colorectal cancer screening programs. <i>United European Gastroenterology Journal</i> , 2017, 5, 255-260.	1.6	46
12	Immunogenicity and mechanisms impairing the response to vaccines in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2015, 21, 11273.	1.4	46
13	<i>Helicobacter Pylori</i> First-Line and Rescue Treatments in the Presence of Penicillin Allergy. <i>Digestive Diseases and Sciences</i> , 2015, 60, 458-464.	1.1	42
14	Endoscopist characteristics that influence the quality of colonoscopy. <i>Endoscopy</i> , 2016, 48, 241-247.	1.0	42
15	The Interplay between Immune System and Microbiota in Inflammatory Bowel Disease: A Narrative Review. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3076.	1.8	35
16	Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple or concomitant treatment to eradicate <i>H. pylori</i> infection. <i>Scandinavian Journal of Gastroenterology</i> , 2013, 48, 652-656.	0.6	32
17	Effect of oral anticoagulants on the outcome of faecal immunochemical test. <i>British Journal of Cancer</i> , 2014, 110, 1334-1337.	2.9	30
18	Immunomodulatory Effect of Gut Microbiota-Derived Bioactive Peptides on Human Immune System from Healthy Controls and Patients with Inflammatory Bowel Disease. <i>Nutrients</i> , 2019, 11, 2605.	1.7	26

#	ARTICLE	IF	CITATIONS
19	Risk of Advanced Proximal Neoplasms According to Distal Colorectal Findings: Comparison of Sigmoidoscopy-Based Strategies. <i>Journal of the National Cancer Institute</i> , 2013, 105, 878-886.	3.0	25
20	Impact of age- and gender-specific cut-off values for the fecal immunochemical test for hemoglobin in colorectal cancer screening. <i>Digestive and Liver Disease</i> , 2016, 48, 542-551.	0.4	23
21	Efficacy and Safety of Quinolone-Containing Rescue Therapies After the Failure of Non-Bismuth Quadruple Treatments for <i>Helicobacter pylori</i> Eradication: Systematic Review and Meta-Analysis. <i>Drugs</i> , 2017, 77, 765-776.	4.9	23
22	Two-week, high-dose proton pump inhibitor, moxifloxacin triple <i>Helicobacter pylori</i> therapy after failure of standard triple or non-bismuth quadruple treatments. <i>Digestive and Liver Disease</i> , 2015, 47, 108-113.	0.4	22
23	Serum adipokines as non-invasive biomarkers in Crohn's disease. <i>Scientific Reports</i> , 2020, 10, 18027.	1.6	16
24	Rate of Detection of Advanced Neoplasms in Proximal Colon by Simulated Sigmoidoscopy vs Fecal Immunochemical Tests. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1708-1716.e4.	2.4	13
25	Fendrix vs Engerix-B for Primo-Vaccination Against Hepatitis B Infection in Patients With Inflammatory Bowel Disease: A Randomized Clinical Trial. <i>American Journal of Gastroenterology</i> , 2020, 115, 1802-1811.	0.2	12
26	Lunasin Peptide is a Modulator of the Immune Response in the Human Gastrointestinal Tract. <i>Molecular Nutrition and Food Research</i> , 2021, 65, e2001034.	1.5	11
27	Peptides encrypted in the human intestinal microbial-exoproteome as novel biomarkers and immunomodulatory compounds in the gastrointestinal tract. <i>Journal of Functional Foods</i> , 2019, 52, 459-468.	1.6	9
28	Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn's disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 588-596.	0.8	6
29	Profiling of Human Circulating Dendritic Cells and Monocyte Subsets Discriminates Between Type and Mucosal Status in Patients With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 268-274.	0.9	6
30	Su1171 Second-Line Rescue Triple Therapy With Levofloxacin After Failure of Non-Bismuth Quadruple or Concomitant Treatment to Eradicate <i>H. pylori</i> Infection. <i>Gastroenterology</i> , 2014, 146, S-394.	0.6	5
31	Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481987420.	1.4	5
32	A quick flow cytometry protocol to assess <i>Helicobacter pylori</i> viability. <i>Journal of Microbiological Methods</i> , 2020, 177, 106043.	0.7	5
33	Optimum second-line regimens for <i>Helicobacter pylori</i> eradication. <i>The Cochrane Library</i> , 2014, , .	1.5	1
34	Functional rare variants influence the clinical response to anti-TNF therapy in Crohn's disease. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481986784.	1.4	1